Literature DB >> 32434413

Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.

Jorge R Georgakopoulos1, Jensen Yeung1,2,3,4.   

Abstract

Entities:  

Keywords:  COVID-19; dermatology; dupilumab; psoriasis

Mesh：

Substances：

Year:  2020        PMID： 32434413     DOI： 10.1177/1203475420930223

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN： 1203-4754            Impact factor:   2.092


× No keyword cloud information.
  1 in total

Review 1.  Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients.

Authors:  Amr Ehab El-Qushayri; Mariam Abdelmageed Mahmoud; Samar Salman; Sameh Sarsik; Beatrice Nardone
Journal:  Dermatol Ther       Date:  2022-04-07       Impact factor: 3.858
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.